相似文献
1
Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela.
J Clin Microbiol. 2001 Jun;39(6):2348-50. doi: 10.1128/JCM.39.6.2348-2350.2001.
2
Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
FEMS Yeast Res. 2007 Jan;7(1):152-64. doi: 10.1111/j.1567-1364.2006.00128.x.
3
Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
Mycoses. 2010 Jan;53(1):62-7. doi: 10.1111/j.1439-0507.2008.01662.x. Epub 2009 Jun 4.
4
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group.
J Infect Dis. 1996 Oct;174(4):812-20. doi: 10.1093/infdis/174.4.812.
5
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
Antimicrob Agents Chemother. 1996 Mar;40(3):822-4. doi: 10.1128/AAC.40.3.822.
6
Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Diagn Microbiol Infect Dis. 2009 Jun;64(2):146-51. doi: 10.1016/j.diagmicrobio.2009.02.007. Epub 2009 Apr 2.
7
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
Diagn Microbiol Infect Dis. 1995 Nov;23(3):99-103. doi: 10.1016/0732-8893(95)00169-7.
8
Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas.
Mycopathologia. 2005 Jan;159(1):7-11. doi: 10.1007/s11046-004-9618-4.
9
Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
Clin Microbiol Infect. 2013 Aug;19(8):763-9. doi: 10.1111/1469-0691.12019. Epub 2012 Oct 3.
10
Phenotypic switching and genetic diversity of Cryptococcus neoformans.
J Clin Microbiol. 2001 Jun;39(6):2060-4. doi: 10.1128/JCM.39.6.2060-2064.2001.
引用本文的文献
1
and Species Complexes in Latin America: A Map of Molecular Types, Genotypic Diversity, and Antifungal Susceptibility as Reported by the Latin American Cryptococcal Study Group.
J Fungi (Basel). 2021 Apr 9;7(4):282. doi: 10.3390/jof7040282.
2
The status of cryptococcosis in Latin America.
Mem Inst Oswaldo Cruz. 2018;113(7):e170554. doi: 10.1590/0074-02760170554. Epub 2018 Apr 5.
3
ANTIFUNGAL SUSCEPTIBILITY TESTING AND GENOTYPING CHARACTERIZATION OF Cryptococcus neoformans AND gattii ISOLATES FROM HIV-INFECTED PATIENTS OF RIBEIRÃO PRETO, SÃO PAULO, BRAZIL.
Rev Inst Med Trop Sao Paulo. 2016 Sep 22;58:69. doi: 10.1590/S1678-9946201658069.
4
Cryptococcus gattii infections.
Clin Microbiol Rev. 2014 Oct;27(4):980-1024. doi: 10.1128/CMR.00126-13.
5
Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.
Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1377-91. doi: 10.1007/s10096-013-1915-8. Epub 2013 Jul 4.
6
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.
J Antimicrob Chemother. 2013 Nov;68(11):2435-44. doi: 10.1093/jac/dkt221. Epub 2013 Jun 20.
7
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
Antimicrob Agents Chemother. 2012 Jun;56(6):3107-13. doi: 10.1128/AAC.06252-11. Epub 2012 Mar 5.
8
Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1647-52. doi: 10.1007/s10096-011-1488-3. Epub 2012 Jan 26.
9
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
J Clin Microbiol. 2009 Jan;47(1):117-23. doi: 10.1128/JCM.01747-08. Epub 2008 Nov 12.
10
Cryptococcus neoformans, Cryptococcus gattii: serotypes in Venezuela.
Mycopathologia. 2008 Sep;166(3):149-53. doi: 10.1007/s11046-008-9132-1. Epub 2008 May 30.
本文引用的文献
1
Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City.
J Clin Microbiol. 2000 May;38(5):1974-6. doi: 10.1128/JCM.38.5.1974-1976.2000.
2
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.
J Clin Microbiol. 1997 Sep;35(9):2243-51. doi: 10.1128/jcm.35.9.2243-2251.1997.
3
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
Antimicrob Agents Chemother. 1996 Mar;40(3):822-4. doi: 10.1128/AAC.40.3.822.
4
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
Diagn Microbiol Infect Dis. 1995 Nov;23(3):99-103. doi: 10.1016/0732-8893(95)00169-7.
5
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.
Clin Microbiol Rev. 1995 Oct;8(4):515-48. doi: 10.1128/CMR.8.4.515.
6
Clinical epidemiological study of 171 cases of cryptococcosis.
Clin Infect Dis. 1994 Mar;18(3):369-80. doi: 10.1093/clinids/18.3.369.
7
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).
J Clin Microbiol. 1982 Mar;15(3):535-7. doi: 10.1128/jcm.15.3.535-537.1982.
8
Separation of chromosomes of Cryptococcus neoformans by pulsed field gel electrophoresis.
Infect Immun. 1989 Sep;57(9):2624-7. doi: 10.1128/iai.57.9.2624-2627.1989.
9
Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil.
Mycopathologia. 1992 Sep;119(3):133-6. doi: 10.1007/BF00448809.
Zotero 插件